We read with interest the study by Izquierdo
et al
. that reported a lower proportion of patients with concurrent asthma and COVID-19, compared to other chronic diseases [1]. During the ongoing pandemic, various studies have also observed a lower occurrence of persons with asthma amongst hospitalised COVID-19 cases [2, 3]. Several hypotheses have been postulated to account for these observations, including lower susceptibility to COVID-19 amongst patients with asthma [2, 3] and a remission in rates of common circulating respiratory viral infections (RVIs) [4]. RVIs are potential triggers of asthma exacerbations and may cause a loss of asthma control [5]. During the COVID-19 pandemic, community-wide public health measures introduced to reduce transmission of SARS-CoV-2, such as universal masking and social distancing, may reduce community transmission of common RVIs [4], potentially decreasing the frequency and severity of asthma exacerbations and hence reducing hospitalisations. However, patients may demonstrate a higher threshold to seek care due to fear of nosocomial transmission during the pandemic. Significant community transmission of SARS-CoV-2 may thus confound causal interpretation of trends in asthma hospitalisations. While the ongoing pandemic provides a rare opportunity to ascertain the impact of public-health measures on hospitalisations for asthma exacerbations, such observations are only possible in areas that have mitigated community transmission and maintained public-health interventions over a sustained duration.